Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...

Concerns about HA-based HDAC inhibitors such as genotoxicity, rapid clearance and extensive metabolite formation, led CKD’s research team to identify a series of NHA molecules that selectively ...

近日，中国科学院广州生物医药与健康研究院孔祥谦研究员与山东大学药学院侯旭奔副教授团队合作，以“Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity”为题在美国化学会期刊Journal of ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (20 December 2024) granted a conditional marketing ...

UK MHRA grants conditional marketing authorisation to Italfarmaco’s givinostat to treat patients with Duchenne muscular dystrophy: United Kingdom Tuesday, December 24, 2024, 12: ...

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has divulged compounds acting as histone deacetylase 1 (HDAC1) and/or 2 (HDAC2) inhibitors reported to be useful for the treatment of cancer.

In contrast, in the new trial combining an HDAC inhibitor with the immunotherapy, 3 of 27 patients had deep tumor shrinkage from the drug combination. In future studies, the team hopes to ...

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report)’s share price fell 0.7% on Wednesday . The company traded as low as $0.61 and last traded at $0.61. 40,294 shares were traded ...

The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA ...